Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States.

JAMA network open - 1 Oct 2020

Guzauskas Gregory F, Garbett Shawn, Zhou Zilu, Spencer Scott J, Smith Hadley S, Hao Jing, Hassen Dina, Snyder Susan R, Graves John A, Peterson Josh F, Williams Marc S, Veenstra David L

Abstract excerpt

Importance: Genomic screening for hereditary breast and ovarian cancer (HBOC) in unselected women offers an opportunity to prevent cancer morbidity and mortality, but the potential clinical impact and cost-effectiveness of such screening have not been well studied. Objective: To estimate the lifetime incremental incidence of HBOC and the quality-adjusted life-years (QALYs), costs, and cost-effectiveness of HBOC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Cost-Benefit Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Predisposition to Disease

Share to Incidence

Share to Mass Screening

Share to Ovarian Neoplasms

Share to Quality-Adjusted Life Years

Share to United States

Source

Open in PubMed Open full text

Identifiers

PMID: 33119106
DOI: 10.1001/jamanetworkopen.2020.22874
PMCID: PMC7596578

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States.PMID 33119106Read ↗

Cost-Effectiveness of Population-Based Multigene Testing for Breast and Ovarian Cancer PreventionSemantic proximity Read ↗

A review of the cost-effectiveness of genetic testing for germline variants in familial cancerSemantic proximity Read ↗

Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers.Semantic proximity Read ↗

A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.Semantic proximity Read ↗

Cost-Effectiveness of BRCA 1/2 Genetic Test and Preventive Strategies: Using Real-World Data From an Upper-Middle Income CountrySemantic proximity Read ↗

Risk-reducing mastectomy and salpingo-oophorectomy in women with hereditary breast and ovarian cancer: a single-institute experience following coverage by Japanese national medical insurance.Semantic proximity Read ↗

Cost-effectiveness of testing for breast cancer susceptibility genes.Semantic proximity Read ↗

Decision-analytic evaluation of the comparative effectiveness and cost-effectiveness of strategies to prevent breast and ovarian cancer in German women with BRCA-1/2 mutations.Semantic proximity Read ↗

Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer.Semantic proximity Read ↗

A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer.Semantic proximity Read ↗

Management of ovarian and breast cancer risk in non-BRCA HBOC pathogenic variant carriers in a large California health care system.Semantic proximity Read ↗

Testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes: a decision analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.